Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 6/20 | 0.42 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL222561 | 1.00 | SIGMAR1 (0.42) | SIGMAR1TMEM97AADAT | |
| SCHEMBL15503355 | 0.83 | AADAT (0.47) | SIGMAR1TMEM97AADAT | |
| SCHEMBL222279 | 0.82 | SIGMAR1 (0.51) | SIGMAR1TMEM97AADAT | |
| SCHEMBL221805 | 0.74 | SIGMAR1 (0.47) | SIGMAR1TMEM97AADAT | |
| SCHEMBL15957793 | 0.73 | SIGMAR1 (0.41) | SIGMAR1TMEM97AADAT | |
| SCHEMBL19730690 | 0.72 | SIGMAR1 (0.41) | SIGMAR1TMEM97AADAT | |
| SCHEMBL221048 | 0.71 | AADAT (0.48) | SIGMAR1TMEM97AADAT | |
| SCHEMBL15958257 | 0.71 | AADAT (0.48) | SIGMAR1TMEM97AADAT | |
| SCHEMBL15957792 | 0.70 | SIGMAR1 (0.49) | SIGMAR1TMEM97AADAT | |
| SCHEMBL4764757 | 0.70 | AADAT (0.46) | SIGMAR1TMEM97AADAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180298011-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2018-10-18 | — | — | US | disclosed |
| US-9957275-B2 | Pyrazolo[1,5-A]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170362244-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170190708-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| EP-3012258-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AND -TRIAZINES AS ANTIVIRAL AGENTS | Gilead Sciences, Inc. (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2585467-B1 | PYRAZOLO[1,5-A]PYRIMIDINES AND -TRIAZINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES INC (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20140072554-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2014-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362244-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | SIGMAR1 3564/4885TMEM97 3929/4885AADAT 632/4885 |
| US-20170190708-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | SIGMAR1 3564/4885TMEM97 3929/4885AADAT 632/4885 |
| US-20140072554-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | SIGMAR1 3564/4885TMEM97 3929/4885AADAT 632/4885 |
| US-20180298011-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | SIGMAR1 3564/4885TMEM97 3929/4885AADAT 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.